Aurobindo Pharma Limited (AUROPHARMA) - Net Assets

Latest as of March 2026: Rs378.83 Billion INR ≈ $4.10 Billion USD

Based on the latest financial reports, Aurobindo Pharma Limited (AUROPHARMA) has net assets worth Rs378.83 Billion INR (≈ $4.10 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs585.02 Billion ≈ $6.33 Billion USD) and total liabilities (Rs206.19 Billion ≈ $2.23 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AUROPHARMA tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs378.83 Billion
% of Total Assets	64.75%
Annual Growth Rate	19.7%
5-Year Change	54.16%
10-Year Change	304.13%
Growth Volatility	13.75

Aurobindo Pharma Limited - Net Assets Trend (2004–2026)

This chart illustrates how Aurobindo Pharma Limited's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Aurobindo Pharma Limited to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Aurobindo Pharma Limited (2004–2026)

The table below shows the annual net assets of Aurobindo Pharma Limited from 2004 to 2026. For live valuation and market cap data, see Aurobindo Pharma Limited (AUROPHARMA) market capitalisation.

Year	Net Assets	Change
2026-03-31	Rs378.83 Billion ≈ $4.10 Billion	+16.04%
2025-03-31	Rs326.47 Billion ≈ $3.53 Billion	+9.37%
2024-03-31	Rs298.51 Billion ≈ $3.23 Billion	+11.17%
2023-03-31	Rs268.52 Billion ≈ $2.90 Billion	+9.27%
2022-03-31	Rs245.74 Billion ≈ $2.66 Billion	+12.06%
2021-03-31	Rs219.29 Billion ≈ $2.37 Billion	+30.34%
2020-03-31	Rs168.25 Billion ≈ $1.82 Billion	+21.11%
2019-03-31	Rs138.92 Billion ≈ $1.50 Billion	+18.92%
2018-03-31	Rs116.82 Billion ≈ $1.26 Billion	+24.62%
2017-03-31	Rs93.74 Billion ≈ $1.01 Billion	+37.49%
2016-03-31	Rs68.18 Billion ≈ $737.31 Million	+31.57%
2015-03-31	Rs51.82 Billion ≈ $560.38 Million	+37.23%
2014-03-31	Rs37.76 Billion ≈ $408.34 Million	+44.02%
2013-03-31	Rs26.22 Billion ≈ $283.53 Million	+11.57%
2012-03-31	Rs23.50 Billion ≈ $254.13 Million	-4.05%
2011-03-31	Rs24.49 Billion ≈ $264.85 Million	+33.58%
2010-03-31	Rs18.33 Billion ≈ $198.28 Million	+47.33%
2009-03-31	Rs12.44 Billion ≈ $134.58 Million	+10.39%
2008-03-31	Rs11.27 Billion ≈ $121.91 Million	+26.72%
2007-03-31	Rs8.90 Billion ≈ $96.20 Million	+8.84%
2006-03-31	Rs8.17 Billion ≈ $88.39 Million	+14.39%
2005-03-31	Rs7.14 Billion ≈ $77.27 Million	-1.45%
2004-03-31	Rs7.25 Billion ≈ $78.40 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Aurobindo Pharma Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2026)

Component	Amount	Percentage
Common Stock	Rs580.80 Million	0.15%
Other Components	Rs378.33 Billion	99.85%
Total Equity	Rs378.91 Billion	100.00%

Aurobindo Pharma Limited Competitors by Market Cap

The table below lists competitors of Aurobindo Pharma Limited ranked by their market capitalization.

Company	Market Cap
Argan Inc NYSE:AGX	$8.69 Billion
S-Oil Corp KO:010950	$8.71 Billion
Grupo Cibest S.A. NYSE:CIB	$8.72 Billion
Aurora Innovation Inc NASDAQ:AUR	$8.73 Billion
Sunoco LP NYSE:SUN	$8.68 Billion
Frontline Ltd OL:FRO	$8.68 Billion
Tianshui Huatian Technology Co Ltd SHE:002185	$8.67 Billion
Alstom S.A. PA:ALO	$8.66 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Aurobindo Pharma Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2025 to 2026, total equity changed from 326,533,200,000 to 378,909,700,000, a change of 52,376,500,000 (16.0%).
Net income of 35,047,500,000 contributed positively to equity growth.
Dividend payments of 2,324,000,000 reduced retained earnings.
Other comprehensive income decreased equity by 22,984,800,000.
Other factors increased equity by 42,637,800,000.

Equity Change Factors (2025 to 2026)

Factor	Impact	Contribution
Net Income	Rs35.05 Billion	+9.25%
Dividends Paid	Rs2.32 Billion	-0.61%
Other Comprehensive Income	Rs-22.98 Billion	-6.07%
Other Changes	Rs42.64 Billion	+11.25%
Total Change	Rs-	16.04%

Book Value vs Market Value Analysis

This analysis compares Aurobindo Pharma Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.14x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 92.76x to 2.14x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2004-03-31	Rs15.06	Rs1396.70	x
2005-03-31	Rs14.05	Rs1396.70	x
2006-03-31	Rs14.64	Rs1396.70	x
2007-03-31	Rs13.35	Rs1396.70	x
2008-03-31	Rs16.65	Rs1396.70	x
2009-03-31	Rs19.17	Rs1396.70	x
2010-03-31	Rs28.93	Rs1396.70	x
2011-03-31	Rs38.20	Rs1396.70	x
2012-03-31	Rs40.18	Rs1396.70	x
2013-03-31	Rs44.72	Rs1396.70	x
2014-03-31	Rs64.24	Rs1396.70	x
2015-03-31	Rs88.32	Rs1396.70	x
2016-03-31	Rs120.77	Rs1396.70	x
2017-03-31	Rs160.14	Rs1396.70	x
2018-03-31	Rs199.35	Rs1396.70	x
2019-03-31	Rs237.07	Rs1396.70	x
2020-03-31	Rs287.14	Rs1396.70	x
2021-03-31	Rs374.27	Rs1396.70	x
2022-03-31	Rs419.43	Rs1396.70	x
2023-03-31	Rs458.07	Rs1396.70	x
2024-03-31	Rs509.32	Rs1396.70	x
2025-03-31	Rs560.22	Rs1396.70	x
2026-03-31	Rs652.35	Rs1396.70	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Aurobindo Pharma Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 9.25%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 10.41%
• Asset Turnover: 0.58x
• Equity Multiplier: 1.54x
Recent ROE (9.25%) is below the historical average (16.92%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2004	15.01%	7.22%	0.81x	2.58x	Rs362.62 Million
2005	0.46%	0.25%	0.62x	2.99x	Rs-680.74 Million
2006	8.55%	4.37%	0.59x	3.30x	Rs-117.87 Million
2007	22.68%	9.47%	0.61x	3.96x	Rs1.12 Billion
2008	21.22%	9.79%	0.67x	3.23x	Rs1.26 Billion
2009	8.08%	3.26%	0.73x	3.40x	Rs-238.66 Million
2010	30.67%	15.69%	0.75x	2.62x	Rs3.78 Billion
2011	23.05%	12.86%	0.75x	2.40x	Rs3.19 Billion
2012	-5.28%	-2.72%	0.73x	2.67x	Rs-3.57 Billion
2013	11.28%	5.00%	0.81x	2.79x	Rs332.84 Million
2014	42.02%	12.99%	1.28x	2.53x	Rs12.01 Billion
2015	30.56%	12.99%	0.94x	2.50x	Rs10.60 Billion
2016	28.70%	14.66%	0.87x	2.26x	Rs13.19 Billion
2017	24.56%	15.41%	0.92x	1.73x	Rs13.64 Billion
2018	20.75%	14.72%	0.78x	1.81x	Rs12.55 Billion
2019	17.02%	12.09%	0.74x	1.90x	Rs9.76 Billion
2020	16.91%	12.32%	0.80x	1.72x	Rs11.63 Billion
2021	24.33%	21.53%	0.73x	1.54x	Rs31.42 Billion
2022	10.78%	11.29%	0.69x	1.38x	Rs1.91 Billion
2023	7.18%	7.75%	0.62x	1.49x	Rs-7.56 Billion
2024	10.63%	10.94%	0.64x	1.51x	Rs1.89 Billion
2025	10.68%	10.99%	0.64x	1.52x	Rs2.21 Billion
2026	9.25%	10.41%	0.58x	1.54x	Rs-2.84 Billion

Industry Comparison

This section compares Aurobindo Pharma Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $16,633,810,657
Average return on equity (ROE) among peers: 18.50%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Aurobindo Pharma Limited (AUROPHARMA)	Rs378.83 Billion	15.01%	0.54x	$8.69 Billion
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$1.33 Billion	3.53%	1.28x	$24.20 Million
Aarti Drugs Limited (AARTIDRUGS)	$1.76 Billion	12.24%	2.47x	$366.49 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$2.27 Million	-2.03%	0.10x	$626.77 Million
Abbott India Limited (ABBOTINDIA)	$8.33 Billion	20.02%	0.37x	$6.00 Billion
Ajanta Pharma Limited (AJANTPHARM)	$2.98 Billion	25.93%	1.18x	$4.16 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$30.64 Billion	11.04%	0.34x	$988.23 Million
Alkem Laboratories Limited (ALKEM)	$88.47 Billion	18.60%	0.59x	$6.92 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$183.78 Million	32.19%	1.01x	$169.18 Million
Alembic Pharmaceuticals Limited (APLLTD)	$16.01 Billion	44.99%	0.54x	$1.59 Billion

About Aurobindo Pharma Limited

NSE:AUROPHARMA India Drug Manufacturers - Specialty & Generic

Market Cap

$8.69 Billion

Rs803.63 Billion INR

Market Cap Rank

#2509 Global

#97 in India

Share Price

Rs1396.70

Change (1 day)

-0.82%

52-Week Range

Rs1022.20 - Rs1517.50

All Time High

Rs1568.05